Clinical Trials
21 trialsNCT05916313 2026-06-02
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT05094336 2026-05-28
MTAPESTRY 101
Amgen
Phase 1/2 Active not recruiting
NCT05736406 2026-05-22
A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma
Hemerion Therapeutics
Phase 1/2 Active not recruiting
NCT06413706 2026-05-22
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Eli Lilly and Company
Phase 2 Active not recruiting
NCT07042620 2026-05-14
A Study to Test a New Fluid to Improve the Quality of Images Obtained by Using Sound Waves (Ultrasound) During Surgery
SonoClear AS
Phase NA Active not recruiting
NCT04521686 2026-04-22
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
NCT02381886 2026-04-13
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Novartis
Phase 1 Active not recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT02650401 2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT04458272 2026-03-20
A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma
Daiichi Sankyo
Phase 2 Active not recruiting
NCT03478462 2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1 Active not recruiting
NCT05610891 2026-03-18
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
Cellectar Biosciences, Inc.
Phase 1 Active not recruiting
NCT03030066 2026-02-04
Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas
Daiichi Sankyo
Phase 1 Active not recruiting
NCT05023551 2025-09-16
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
Sumitomo Pharma America, Inc.
Phase EARLY_PHASE1 Active not recruiting
NCT05342883 2025-09-05
GESTALT
GT Medical Technologies, Inc.
Phase 4 Active not recruiting
NCT01473485 2025-05-01
ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Brain Tumors
InSightec
Phase NA Active not recruiting
NCT05664243 2025-05-01
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
In8bio Inc.
Phase 1/2 Active not recruiting
NCT04164901 2025-04-03
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
Servier
Phase 3 Active not recruiting
NCT05561374 2024-11-29
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
Oblato, Inc.
Phase 1 Active not recruiting
NCT05969691 2023-08-08
Radiomics-Based Visualization and Quantitative Validation of IDH1 Heterogeneity in Gliomas
Mingge LLC
Phase NA Active not recruiting
NCT05656053 2023-03-17
Intraoperative Rapid Diagnosis of Glioma Based on Fusion of Magnetic Resonance and Ultrasound Imaging
Mingge LLC
Active not recruiting